J P Grüfeld

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
We have studied the effects of intravenous infusion of saralasin, a competitive antagonist of angiotensin II, in 27 hypertensive patients: 13 had essential hypertension, 14 had renal lesions which involved the renal artery in 9 cases. In essential hypertensives saralasin administration did not significantly lower blood pressure, even after mild salt(More)
  • 1